Company Overview and News

46
[Press] Middle East Oilfield Services Market - Analysis of Growth, Trends and Forecasts (2018 - 2023)

2018-04-12 oilvoice
The Middle East produces more than 30% of the crude oil produced globally, and had 385 drilling rigs in October 2017. After the crude oil price started increasing in the second half of 2016, the oil & gas activity in the region started stabilizing slowly. In November 2017, crude oil price crossed USD 60 barrel mark. The region is expected to witness an increase in oil & gas activity in 2018, with Saudi Arabia being the leader, and Iran and Iraq to register a high growth rate.
BHI SLB ESV TKPPY WFT SPMI CHOLY 2883 CHOLF SCL SLB NBR

3
[Press] Oil & Gas EPC Market - Analysis of Growth, Trends and Forecasts (2018 - 2023)

2018-04-12 oilvoice
In 2016, the global spending on oil and gas projects was about USD 437 billion, a decrease of nearly 41.7% when compared to that of 2014. Factors, such as a decline in the investments in oil and gas projects and cancellation of projects, worth USD 380 billion since 2014, have resulted in a severe downturn in the global oil & gas EPC market. As a result, it is tough to maintain the profit margins, which has fueled the level of competition between EPC contractors.
JEC TKPPY SPMI FLR MDR KBR MCDFF

14
Uganda Signs Agreement with Investors to Build Oil Refinery

2018-04-10 rigzone
KAMPALA, April 10 (Reuters) - Uganda signed an agreement on Tuesday with a consortium, including a subsidiary of America's General Electric, to build and operate an oil refinery in western Uganda that will cost $3 billion-$4 billion, the president's office said.
GEC GE SPMI GNE TLW

0
Rabat Deep 1 Well Spuds

2018-03-14 rigzone
The Saipem 1200 drillship has commenced the drilling of the Rabat Deep 1 well in Morocco, according to a statement from Chariot Oil & Gas Limited.
SPMI

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...